- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Brentuximab Vedotin.
Displaying page 1 of 2.
EudraCT Number: 2012-004128-39 | Sponsor Protocol Number: C25006 | Start Date*: 2013-07-08 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 4, Open–label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | |||||||||||||
Medical condition: Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Ongoing) BE (Ongoing) PT (Ongoing) ES (Ongoing) PL (Ongoing) HU (Completed) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003946-17 | Sponsor Protocol Number: FIL_PTCL_BV | Start Date*: 2015-09-15 |
Sponsor Name:Fondazione Italiana Linfomi ONLUS | ||
Full Title: Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients | ||
Medical condition: RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T CELL LYMPHOMA (PTCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000873-59 | Sponsor Protocol Number: Uni-Koeln-3263 | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma | |||||||||||||
Medical condition: disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005950-27 | Sponsor Protocol Number: 202100762 | Start Date*: 2023-03-29 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma | ||
Medical condition: All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including: Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lympho... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002347-41 | Sponsor Protocol Number: CA209-744 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin... | |||||||||||||
Medical condition: Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) IE (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) PL (Completed) Outside EU/EEA IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001211-21 | Sponsor Protocol Number: HO136 | Start Date*: 2017-04-14 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in fir... | |||||||||||||
Medical condition: CD30 positive diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) NL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002012-46 | Sponsor Protocol Number: BV-ABVD | Start Date*: 2012-11-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin Lymphoma | |||||||||||||
Medical condition: Previously untreated patients with classical Hodgkin Lymphoma according to the World Health Organisation (WHO) classification | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004109-24 | Sponsor Protocol Number: FIL_BVHD01 | Start Date*: 2014-07-14 |
Sponsor Name:Fondazione Italiana Linfomi Onlus | ||
Full Title: A phase II study of Brentuximab Vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease | ||
Medical condition: elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003286-28 | Sponsor Protocol Number: CA209-436 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression | |||||||||||||
Medical condition: Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003084-21 | Sponsor Protocol Number: cHL-PG01 | Start Date*: 2020-01-13 | |||||||||||
Sponsor Name:PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA | |||||||||||||
Full Title: A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgki... | |||||||||||||
Medical condition: Patients with relapsed or refractory cHL that has not responded to, or has progressed after, the previous treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002782-57 | Sponsor Protocol Number: IMIS2015-03 | Start Date*: 2016-11-22 |
Sponsor Name:Institut des maladies génétiques - Imagine | ||
Full Title: Phase 2 study of Brentuximab Vedotin associated with CHP followed by consolidation with high-dose therapy / autologous stem-cell transplantation as frontline treatment of patients with enteropathy-... | ||
Medical condition: enteropathy-associated T-cell lymphoma type 1 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002746-21 | Sponsor Protocol Number: GELTAMO18-HL | Start Date*: 2020-04-29 | |||||||||||
Sponsor Name:Fundación GELTAMO | |||||||||||||
Full Title: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentux... | |||||||||||||
Medical condition: Patients with Relapsed /Refractory Classical Hodgkin's Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GR (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003689-28 | Sponsor Protocol Number: BrEPEM-LH-22017 | Start Date*: 2018-04-05 | |||||||||||
Sponsor Name:GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea) | |||||||||||||
Full Title: A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Ly... | |||||||||||||
Medical condition: Older Patients with Untreated Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005382-79 | Sponsor Protocol Number: FIL-BBV | Start Date*: 2015-09-15 | ||||||||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | ||||||||||||||||||
Full Title: A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30 + peripheral T-cell lymphoma in first salvage setting: the BBV regimen. | ||||||||||||||||||
Medical condition: Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004027-17 | Sponsor Protocol Number: SGN35-027 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:Seagen Inc. | |||||||||||||
Full Title: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects | |||||||||||||
Medical condition: Classical Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) PL (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001263-70 | Sponsor Protocol Number: IIBSP-CAR-2019-30 | Start Date*: 2020-03-03 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 sp... | ||
Medical condition: Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002544-32 | Sponsor Protocol Number: UCL/15/0515 | Start Date*: 2018-03-01 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ... | ||||||||||||||||||
Medical condition: Relapsed/refractory Hodgkin lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020363-21 | Sponsor Protocol Number: SGN35-010 | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma | |||||||||||||
Medical condition: Patients who were on the placebo arm and experienced progression of HL while participating in the SGN35-005 clinical study | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003526-80 | Sponsor Protocol Number: CLSG-PTCL-CHEPA | Start Date*: 2021-12-16 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Kooperativní lymfomová skupina, z.s. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas. | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Peripheral T-cell lymphomas (PTCL) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000182-37 | Sponsor Protocol Number: BREACH | Start Date*: 2014-08-29 | ||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||
Full Title: BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY IN UNTREATED PATIENTS WITH STAGE I/II UNFAVOURABLE HODGKIN LYMPHOMA - A RANDOMIZED PHASE II LYSA-FIL-EORTC INTERGROUP STUDY | ||||||||||||||||||
Medical condition: Untreated patients with histologically confirmed CD30+ classical Hodgkin lymphoma (stage I/II), aged > or = 18 and < or = 60 years old, with at least one unfavourable clinical pronostic factor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) IT (Ongoing) DK (Completed) NL (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.